Health and Science

FDA allows storage, transport of Pfizer vaccine at higher temperatures

Share
Key Points
  • The U.S. Food and Drug Administration on Thursday approved storage and transportation of Covid-19 vaccine developed by Pfizer and German partner BioNTech at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
  • Last week, the companies had asked the U.S. health regulator to relax requirements for their Covid-19 vaccine to be stored at ultra-low temperatures, potentially allowing it to be kept in pharmacy freezers.

In this article

Boxes containing the Pfizer-BioNTech COVID-19 vaccine are prepared to be shipped at the Pfizer Global Supply Kalamazoo manufacturing plant in Portage, Michigan, December 13, 2020.
Morry Gash | Reuters

The U.S. Food and Drug Administration on Thursday approved storage and transportation of Covid-19 vaccine developed by Pfizer and German partner BioNTech at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.

Last week, the companies had asked the U.S. health regulator to relax requirements for their Covid-19 vaccine to be stored at ultra-low temperatures, potentially allowing it to be kept in pharmacy freezers.

"Alternative temperature for transportation and storage will help ease the burden of procuring ultra-low cold storage equipment for vaccination sites and should help to get vaccine to more sites," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said.

In December, the FDA granted emergency use authorization to the vaccine and current label to be stored at temperatures between -80ºC and -60ºC (-112ºF to -76ºF), meaning it has to be shipped in specially designed containers.